Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8243711 | 0.89 | F10 (0.41) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4911973 | 0.80 | F10 (0.55) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8246070 | 0.73 | F10 (0.39) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8243399 | 0.71 | F10 (0.39) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8242480 | 0.70 | F10 (0.38) | F10 | |
| SCHEMBL4900327 | 0.69 | F10 (0.53) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10313039 | 0.68 | F10 (0.44) | F10CYP3A4CYP2C9 | |
| SCHEMBL4908284 | 0.68 | F10 (0.62) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10313019 | 0.66 | F10 (0.39) | F10NOTUMMIF | |
| SCHEMBL4908733 | 0.65 | F10 (0.58) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007025940-A1 | SUBSTITUTED BIARYLS AND THEIR USE AS FACTOR XA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-08 | — | — | WO | disclosed |